Novel flucytosine loaded in-situ gel for the management of ocular infections
DOI:
https://doi.org/10.56782/pps.350Keywords:
Flucytosine, Poloxamer 407, Gellan gum, HPMC K4M, In-situ ocular gel, Simplex lattice designAbstract
Flucytosine, a BCS class II drug, is indicated in fungal infection. Currently, flucytosine is available in tablet dosage form in the market. However, the drug is indicated for the ocular fungal infections. Thus, there is a need to develop a ocular formulation that can retain for longer duration with prolonged drug release. In the present work, in-situ ocular gel containing flucytosine was prepared for cryptococcosis and candidiasis fungal infection. Design of experiment was employed to obtain the optimized formulation. To determine the independent variables impacting the formulation preparation, preliminary trials were conducted using Poloxamer 407, Poloxamer 188, Carbopol 934, gellan gum, and HPMC K4M as polymer and it was optimized using Simplex lattice design. Amount of poloxamer 407, amount of gellan gum and amount of HPMC K4M were taken as independent variable while viscosity (cps), gelling time (sec), drug release in 6 h were taken as dependent variables. The prepared formulations were evaluated for clarity, pH, viscosity, gelling time, gelling strength, gelling temperature, in-vitro drug release, sterility test and stability studies. Results of the prepared in-situ ocular gel formulation of flucytosine demonstrated significant potential as a therapeutic breakthrough for enhancing treatment outcomes in candidiasis and cryptococcosis infections. Stability studies suggested formulation was stable for at least 6 months. Thus, a successful formulation of flucytosine was developed addressing critical challenges of conventional eye drops and offering prolonged drug release with improved retention in the eye.
Downloads
References
1. Vulovic, N.; Primprac, M.; Stupar, M.; Ford J.L. Some studies on the preservation of indomethacin suspensions intended for ophthalmic use. Int. J. Pharm. 1989, 55(2-3), 123-128. DOI: 10.1016/0378-5173(89)90032-X
2. Gebhardt, B.M.; Varnell, E.D.; Kaufman, H.E. Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. J. Ocul. Pharmacol. Ther. 1995, 11, 509–517. DOI: 10.1089/jop.1995.11.509
3. Vandamme, T.F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog. Retin. Eye Res. 2002, 21, 15–34. DOI: 10.1016/s1350-9462(01)00017-9
4. Lang, J.; Roehrs, R.; Jani, R. The Science and Practice of Pharmacy. In Remington, 7th ed, Lippincott Williams & Wilkins, Philadelphia, 2009, Volume 7, pp. 827-856.
5. Eguchi, H.; Shiota, H.; Oguro, S.; Kasama, T. The inhibitory effect of vancomycin ointment on the manifestation of MRSA keratitis in rabbits. J. Infect. Chemother. 2009, 15, 279–283. DOI: 10.1007/s10156-009-0708-6
6. Gray, C. Systemic toxicity with topical ophthalmic medications in children. Paediatr. Perinat. Drug Ther. 2006, 7, 23-29. DOI: 10.1185/146300905X75334
7. Ishibashi, T.; Yokoi, N.; Kinoshita, S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J. Glaucom. 2003, 12, 486–490. DOI: 10.1097/00061198-200312000-00008
8. Giri, B.R.; Jakka, D.; Sandoval, M.A.; Kulkarni, V.R.; Bao, Q. Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies. Pharmaceutics 2024, 62, Art. No: 1325. DOI: 10.3390/pharmaceutics 16101325
9. Bonacucina, G.; Cespi, M.; Mencarelli, G.; Giorgioni, G.; Palmieri, G.F. Thermosensitive Self-Assembling Block Copolymers as Drug Delivery Systems. Polymers 2011, 3, 779-811. DOI: 10.3390/polym3020779
10. Del Amo, E.M.; Urtti, A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment,” Drug Discov. Today 2008, 3, 135-143. DOI: 10.1016/j.drudis.2007. 11.002
11. Gupta, H.; Aqil, M. Contact lenses in ocular therapeutics,” Drug Discov. Today 2012, 17, 522-527. DOI: 10.1016/j.drudis.2012.01.014
12. Gurny, R.; Ibrahim, H.; Buri, P. The development & use of in situ formed gel triggered by pH. In Biopharmaceutics of ocular drug delivery, CRC Pres, 1992, pp. 81-90.
13. Cohen, S.; Lobel, E.; Trevgoda, A.; Peled, Y. A novel in situ forming ophthalmic drug delivery system from alginates undergoing gelling in the eye. J. Control. Release 1997, 44, 201–208. DOI: 10.1016/S0168-3659(96)01523-4
14. Srividya, B.; Cardoza, R.M.; Amin, P.D. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system,” J. Control. Release 2001, 73, 205-211. DOI: 10.1016/s0168-3659(01)00279-6
15. Qiu, Y.; Park, K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. 2001, 53, 321-339. DOI: 10.1016/ s0169-409x(01)00203-4
16. Mottu, F.; Gailloud, P.; Massuelle, D.; Rüfenacht, D.A.; Doelker, E. In vitro assessment of new embolic liquids prepared from preformed polymers and water-miscible solvents for aneurysm treatment. Biomaterials 2000, 21, 803-811. DOI: 10.1016/s0142-9612(99)00243-4
17. Burkoth, A.K.; Anseth, K.S. A review of photocrosslinked polyanhydrides: in situ forming degradable networks. Biomaterials. 2000, 21, 2395-2404. DOI: 10.1016/s0142-9612(00)00107-1
18. Podual, K.; Doyle, F.J. 3rd.; Peppas, N.A. Dynamic behavior of glucose oxidase-containing microparticles of poly(ethylene glycol)-grafted cationic hydrogels in an environment of changing pH. Biomaterials 2000, 21, 1439-1450. DOI: 10.1016/s0142-9612(00)00020-x
19. Guo, J.H.; Skinner, G.W.; Harcum, W.W.; Barnum, P.E.; Pharmaceutical applications of naturally occurring water soluble polymers. Pharm. Sci. & Technol. Today 1998, 1, 54-61. DOI: 10.1016/S1461-5347(98)00072-8
20. Aderman, C.M.; Gorovoy, I.R.; Chao, D.L.; Bloomer, M.M.; Obeid, A.; Stewart, J.M. Cryptococcal choroiditis in advanced AIDS with clinicopathologic correlation. Am. J. Ophthalmol. Case Rep. 2018, 10, 51-54. DOI: 10.1016/j.ajoc.2018.01.045
21. Phongkhun, K.; Pothikamjorn, T.; Srisurapanont, K.; Manothummetha, K.; Sanguankeo, A.; Thongkam, A.; Chuleerarux, N.; Leksuwankun, S.; Meejun, T.; Thanakitcharu, J.; Walker, M.; Gopinath, S.; Torvorapanit, P.; Langsiri, N.; Worasilchai, N.; Moonla, C.; Plongla, R.; Kates, O.S.; Nematollahi, S.; Permpalung, N. Prevalence of Ocular Candidiasis and Candida Endophthalmitis in Patients With Candidemia: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2023, 76, 1738-1749. DOI: 10.1093/cid/ciad064
22. Vermes, A.; Guchelaar, H.J.; Dankert, J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000, 46, 171–179. DOI: 10.1093/jac/46.2.171
23. Prausnitz, M.R.; Noonan, J.S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 1998, 87, 1479–1488. DOI: 10.1021/js9802594
24. Liu, Y.; Liu, J.; Zhang, X.; Zhang, R.; Huang, Y.; Wu, C. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery. AAPS PharmSciTech. 2010, 11, 610-620. DOI: 10.1208/s12249-010-9413-0
25. Politis, N.S.; Colombo, P.; Colombo, G.; Rekkas, M.D. Design of experiments (DoE) in pharmaceutical development. Drug Dev. Ind. Pharm. 2017, 43, 889-901. DOI: 10.1080/03639045.2017.1291672
26. Fukuda, I.M.; Pinto, C.F.F.; Moreira, C.; Saviano, A.M.; Lourenço, F.R. Design of Experiments (DoE) applied to Pharmaceutical and Analytical Quality by Design (QbD). Brazilian J. Pharm. Sci. 2018, 54(spe), Art. No: e01006. DOI: 10.1590/s2175-97902018000001006
27. Nair, A.B.; Shah, J.; Jacob, S.; Al-Dhubiab, B.E.; Sreeharsha, N.; Morsy, M.A.; Gupta, S.; Attimarad, M.; Shinu, P.; Venugopala, K.N. Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. PLoS One 2021, 16, Art. No: e02488571. DOI: 10.1371/journal.pone.0248857
28. Mandlik, S.K.; Saugat, A.; Ameya, A.D. Application of simplex Lattice design in formulation and development of buoyant matrices of dipyridamole. J. App. Pharm. Sci. 2012, 2, 107-111. DOI: 10.7324/JAPS.2012.21221
29. Jeswani, G.; Chablani, L.; Gupta, U.; Sahoo, R.K.; Nakhate, K.T.; Ajazuddin. Development and optimization of paclitaxel loaded Eudragit/PLGA nanoparticles by simplex lattice mixture design: Exploration of improved hemocompatibility and in vivo kinetics. Biomed. Pharmacother. 2021, 144, Art. No: 112286. DOI: 10.1016/j.biopha.2021.112286
30. Nasser, N.; Hathout, R.M.; Abd-Allah, H.; Sammour, O.A. Simplex Lattice Design and Machine Learning Methods for the Optimization of Novel Microemulsion Systems to Enhance p-Coumaric Acid Oral Bioavailability: In Vitro and In Vivo Studies. AAPS PharmSciTech. 2024, 25, Art. No: 56. DOI: 10.1208/s12249-024-02766-1
31. Wu, Y.; Liu, Y.; Li, X.; Kebebe, D.; Zhang, B.; Ren, J.; Lu, J.; Li, J.; Du, S.; Liu, Z. Research progress of in-situ gelling ophthalmic drug delivery system. Asian J. Pharm. Sci. 2019, 14, 1-15. DOI: 10.1016/j.ajps.2018.04.008
32. Janga, K.Y.; Tatke, A.; Balguri, S.P.; Lamichanne, S.P.; Ibrahim, M.M.; Maria, D.N.; Jablonski, M.M.; Majumdar, S. Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation. Artif. Cells Nanomed. Biotechnol. 2018, 46, 1039-1050. DOI: 10.1080/21691401.2018. 1443117
33. Hu, Y.; Wu, W. Application of Membrane Filtration to Cold Sterilization of Drinks and Establishment of Aseptic Workshop. Food Environ. Virol. 2023, 15, 89-106. DOI: 10.1007/s12560-023-09551-6
34. Çoban, Ö.; Pınar, S.G.; Polat, H.K.; Gedik, G.; Karakuyu, N.F.; Pezik, E.; Ünal, S.; Mokhtare, B.; Akşit, A. Development of Lacosamide-loaded In-Situ Gels through Experimental Design for Evaluation of Ocular Irritation In Vitro and In Vivo. J. Nanomed. 2020, 3, Art. No: 1031. DOI: 10.1016/j.xphs.2024.11.027
35. Sheshala, R.; Wai, N.Z.; Said, I.D.; Ashraf, K.; Lim, S.M.; Ramasamy, K.; Zeeshan, F. Poloxamer and Chitosan-Based In Situ Gels Loaded with Orthosiphon stamineus Benth. Extracts Containing Rosmarinic Acid for the Treatment of Ocular Infections. Turk. J. Pharm. Sci. 2022, 19, 671-680. DOI: 10.4274/tjps.galenos.2021.40121
36. Shanmugam, S.; Valarmathi, S.; Satheesh, K. Sterility Testing Procedure of Ophthalmic Ocusert Aciclovir Used For Treating Herpes Simplex Virus. Asian J. Pharm. Clin. Res. 2017, 10, 344-346. DOI: 10.22159/ajpcr.2017.v10i10.19216
37. Gupta, H.; Malik, A.; Khar, R.K.; Ali, A.; Bhatnagar, A.; Mittal, G. Physiologically active hydrogel (in situ gel) of sparfloxacin and its evaluation for ocular retention using gamma scintigraphy. J. Pharm. Bioallied. Sci. 2015, 7, 195-200. DOI: 10.4103/0975-7406.160015.
38. Kurniawansyah, I.S.; Rusdiana, T.; Sopyan, I.; Ramoko, H.; Wahab, H.A.; Subarnas, A. In situ ophthalmic gel forming systems of poloxamer 407 and hydroxypropyl methyl cellulose mixtures for sustained ocular delivery of chloramphenicole: optimization study by factorial design. Heliyon 2020, 6, Art. No: e05365. DOI: 10.1016/j.heliyon.2020.e05365.
39. Gunasekaran, S.; Seshadri, S.; Muthu, S. Vibrational spectra and normal coordinate analysis of flucytosine. Indian J. Pure Appl. Phy. 2006, 44, 581-586. URL: https://nopr.niscpr.res.in/handle/123456789/8338
40. Segall, A.I. Preformulation: The use of FTIR in compatibility studies. J. Innov. Appl. Pharm. Sci. 2019, 4(3), 01-06. URL: https://saapjournals.org/index.php/jiaps/article/view/198.
41. Biswal, S.; Parmanik, A.; Das, D.; Sahoo, R.N.; Nayak, A.K. Gellan gum-based in-situ gel formulations for ocular drug delivery: A practical approach. Int. J. Biolog. Macromol. 2024, 19, Art. No: 138979. DOI: 10.1016/j.ijbiomac.2024.138979
42. Garala, K.; Joshi, P.; Shah, M.; Ramkishan, A.; Patel, J. Formulation and evaluation of periodontal in situ gel. Int. J. Pharm. Investig. 2013, 3, 29-41. DOI: 10.4103/2230-973X.108961
43. Khare, P.; Chogale, M.M.; Kakade, P.; Patravale, V.B.; Gellan gum-based in situ gelling ophthalmic nanosuspension of Posaconazole. Drug Deliv. Transl. Res. 2022, 12, 2920-2935. DOI: 10.1007/s13346-022-01155-0
44. Satyanarayana, S.D.; Abu Lila, A.S.; Moin, A.; Moglad, E.H.; Khafagy, E.S.; Alotaibi, H.F.; Obaidullah, A.J.; Charyulu, R.N. Ocular Delivery of Bimatoprost-Loaded Solid Lipid Nanoparticles for Effective Management of Glaucoma. Pharmaceuticals (Basel) 2023, 16, Art. No: 1001. DOI: 10.3390/ph16071001
Downloads
Published
Issue
Section
License
Copyright (c) 2025 KOMAL PARMAR, RISHI BHARATIA
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
